Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 91 to 105 of 152 results for multiple sclerosis

  1. Etripamil for treating paroxysmal supraventricular tachycardia [ID6581]

    In development Reference number: GID-TA11750 Expected publication date: TBC

  2. Percutaneous venoplasty for chronic cerebrospinal venous insufficiency for multiple sclerosis (IPG420)

    This guidance has been updated and replaced by NICE interventional procedures guidance 640.

  3. Beta interferon and glatiramer acetate for the treatment of multiple sclerosis (TA32)

    This guidance has been updated and replaced by NICE technology appraisal guidance 527.

  4. The Debrisoft monofilament debridement pad for use in acute or chronic wounds (HTG334)

    Evidence-based recommendations on the Debrisoft monofilament debridement pad for use in acute or chronic wounds.

  5. Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders (TA748)

    Evidence-based recommendations on mexiletine (Namuscla) for treating the symptoms of myotonia in adults with non-dystrophic myotonic disorders.

  6. Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation (TA429)

    Evidence-based recommendations on ibrutinib (Imbruvica) for treating chronic lymphocytic leukaemia in adults.

  7. Cannabidiol for treating seizures caused by tuberous sclerosis complex (TA873)

    Evidence-based recommendations on cannabidiol (Epidyolex) for treating seizures caused by tuberous sclerosis complex.

  8. UroShield for preventing catheter-associated urinary tract infections (HTG620)

    Evidence-based recommendations on UroShield for preventing catheter-associated urinary tract infections.

  9. Mollii suit for spasticity (MIB100)

    NICE has a developed medtech innovation briefing on Mollii suit for spasticity .

  10. Sunlight exposure: risks and benefits (NG34)

    This guideline covers how to communicate the risks and benefits of natural sunlight exposure (specifically, the ultraviolet rays UVA and UVB) to help people understand why they may need to modify their behaviour to reduce their risk of skin cancer and vitamin D deficiency.

  11. Sipavibart for preventing COVID-19 [ID6282]

    In development Reference number: GID-TA11352 Expected publication date: TBC

  12. Quality standards advisory committee members

    Read biographies of the members of our quality standards advisory committee.

  13. Quality standards advisory committee members

    Read biographies of the members of our quality standards advisory committee.

  14. Olipudase alfa for treating acid sphingomyelinase deficiency (Niemann–Pick disease) type AB and type B (HST32)

    Evidence-based recommendations on olipudase alfa (Xenpozyme) for treating acid sphingomyelinase deficiency (Niemann–Pick disease) in people with type AB or type B.

  15. BladderScan BVI 9400 3D portable ultrasound scanner for measuring bladder volume (MIB50)

    NICE has developed a medtech innovation briefing (MIB) on the BladderScan BVI 9400 3D portable ultrasound scanner for measuring bladder volume